Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-142 · 2 trials · 2 indications
FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-142 will be assessed.
Tmax of ABBV-142 will be assessed.
AUCt of ABBV-142 will be determined.
AUCinf of ABBV-142 will be assessed.
Terminal phase elimination rate constant (β) of ABBV-142 will be assessed.
Terminal phase elimination half-life (t1/2) of ABBV-142 will be assessed.
Dose normalized Cmax of ABBV-142 will be assessed.
Dose normalized AUC of ABBV-142 will be assessed.
| Arm | Type | Description |
|---|---|---|
| Substudy 1: ABBV-142 | EXPERIMENTAL | Participants will receive ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period. |
| Substudy 1: Placebo for ABBV-142 | PLACEBO_COMPARATOR | Participants will receive placebo for ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period. |
| Part 1: Group 1 | EXPERIMENTAL | Participants will receive ABBV-142 Dose A or Placebo on Day 1. |
| Part 1: Group 2 | EXPERIMENTAL | Participants will receive ABBV-142 Dose B or Placebo on Day 1. |
| Part 1: Group 3 | EXPERIMENTAL | Participants will receive ABBV-142 Dose C or Placebo on Day 1. |
| Part 1: Group 4 | EXPERIMENTAL | Participants will receive ABBV-142 Dose D or Placebo on Day 1. |
| Part 1: Group 5 (Optional) | EXPERIMENTAL | Participants will receive ABBV-142 Dose TBD or Placebo on Day 1. |
| Part 2: Group 6 | EXPERIMENTAL | Participants will receive ABBV-142 Dose B or Placebo on Day 1. |
| Part 2: Group 7 | EXPERIMENTAL | Participants will receive ABBV-142 Dose C or Placebo on Day 1. |
| Part 3: Group 8 | EXPERIMENTAL | Han Chinese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1. |
| Part 3: Group 9 | EXPERIMENTAL | Japanese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1. |
| Name | Type | Description |
|---|---|---|
| ABBV-142 | DRUG | ABBV-142 |
| Placebo for ABBV-142 | DRUG | Placebo for ABBV-142 |
| Placebo | DRUG | IV Infusion |
Inclusion Criteria: \- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verificatio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
| Trevi Therapeutics, Inc. | TRVI | 1 | PHASE1 | NAL |